Investors are closely watching Eli Lilly & Company (LLY) as the pharmaceutical giant prepares to release its fiscal third-quarter results later this week. Market watchers are expecting strong results driven by the robust sales of Lilly's blockbuster drugs, particularly its insulin portfolio. However, there are also concerns about potential headwind